Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	42
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	36
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	34
Indication-based pricing of the pharmaceuticals in Croatia: case-study	30
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	29
How to create value with constrained budgets in oncological care? A narrative review	21
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	17
Adherence to augmentation therapy for the treatment of major depressive disorder	17
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations	17
Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective	16
Social care data in the UK; current landscape, challenges, and future recommendations	15
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review	13
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	11
Consumption of antidepressants and economic austerity in Brazil	11
The role of insurance policies in the drug pricing landscape	10
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	10
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review	10
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	10
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study	9
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	9
The impact of under-investment on health in Southern and Central Eastern European Countries	9
The impact of bone turnover marker on medication adherence and the health economics-related consequences	9
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	9
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	9
A methodological guide for implementing and interpreting results of probabilistic analysis	9

A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	9
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	8
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review	8
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis	8
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review	8
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	8
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis	8
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	8
Systematic reviews of machine learning in healthcare: a literature review	8
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system	8
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture	8
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	8
Digital measures in epilepsy in low-resourced environments	8
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	8
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands	7
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	7
Economic evaluation of an add-on module to reduce intrusive suicidal mental images in patients with depressive symptoms	7
Systematic review on the use of cost-benefit analysis to evaluate food environment interventions	7
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments	7
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination	7
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	7
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes	7
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care	7
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets	7
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation	7
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	7
How relevant is the BMI for cost-of-illness studies in the 21st century?	7
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve	7
Valuing prevention: lessons and recommendations from a Dutch expert committee	6
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	6
Developing the Lebanese health economic evaluation guideline	6
Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework	6
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama	6
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders	6
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics	6
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation	6
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access	6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change	6
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies	6
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy	6
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries	6
Burden of disease of chronic pain in Ecuador	6
Bridging the gap: enhancing medication adherence through research and innovation	6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions	6
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair	6
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	5
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	5
The hidden burden of atopic dermatitis in central and Eastern European countries	5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	5

Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)	5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	5
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	5
Economic benefits of global Collaborative Health technology	5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review	5
Workplace productivity losses due to cancer: findings from an Australian longitudinal population survey (2009–2021)	5
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study	4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	4
The economics of prevention and quality of care: policy insights from the EU’s COVID-19 response	4
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	4
The value of functional genomics: a contingent valuation	4
The economic impact of pharmacist intervention during pandemics	4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning	4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis	4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	4
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	4
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands	4
Implementing a Managed Entry Agreement Framework in Cyprus	4
Correction	4
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	4
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	4
The Lebanese health economic evaluation guideline	4
Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019–2025): a systematic review	4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China	4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	4
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system	4
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece	4
Digital decision aids and prenatal outcomes: a systematic review and meta-analysis	4
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model	3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves	3
Economics perspectives on understanding antimicrobial use and resistance: a scoping review from theory to practice	3
Integrated care in Western Europe: a wise solution for the future?	3
A review of caregiver costs included in cost-of-illness studies	3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	3
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China	3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece	3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective	3
Burden of disease of chronic pain in Colombia	3
Barriers to digital endpoints in data collection in low and middle-income countries	3
Perspectives in prospective comparative economic evaluations: a systematic review	3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	3
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population	3
Exploring the approach to parameter uncertainty in early economic evaluations of surgical technology – a systematic review	3
Pharmacovigilance and outcomes: experience from Saudi Arabia narrative review	3
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia	3
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	3
Public value judgments about the criteria for reimbursement of medicines in South Korea	3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 2024	3
Cost-utility analysis of Lenvatinib vs. Sorafenib in unresectable hepatocellular carcinoma in Iran	3
Budget impact of low-dose computed tomography screening for lung cancer in Argentina	3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system	3
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program	3
Negating the burden of hip fracture in high-risk populations: a narrative review of epidemiology, costs, and multifaceted mitigation strategies	3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	3
How can patients shape digital medicine? A rapid review of patient and public involvement and engagement in the development of digital health technologies for neurological conditions	3
Willingness to pay for a quality-adjusted life year (QALY) in Pakistan: implications for health policy	3
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	3
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and high-sales biosimilars	3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model	3
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare	3
The health production model and the crucial role of health promotion	3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds	3
Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	3
The short-term impact of copayment reductions for government subsidised medicines in Australia	3
Evaluating high-cost technologies – no need to throw the baby out with the bathwater	2

Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	2
Leveraging sensor-based functional outcomes to enhance understanding of the patient experience: challenges and opportunities	2
The cost-of-illness of multiple sclerosis in Jordan	2
Correction	2
Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States	2
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	2
Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis	2
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019	2
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	2
A retrospective budget impact analysis of fidaxomicin treatment for Clostridioides difficile infections (CDI) in Germany	2
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	2
The economic benefits of fracture prevention	2
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	2
A landscape analysis and discussion of value of gene therapies for sickle cell disease	2
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	2
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	2
Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective	2
Economic burden of suicides and suicide attempts in low- and middle-income countries: a systematic review of costing studies	2
First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis	2
Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina	2
Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma	2
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	2
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	2
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	2
Cost-effectiveness of cholecystectomy compared to conservative management in people presenting with uncomplicated symptomatic gallstones or cholecystitis in India	2
How should we measure the use of social care and informal care?	2
Conceptualization of a decision-analytic model in youth mental health: an application of stakeholder engagement in model development in the Netherlands	2
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China	2
Multicenter, cross-sectional study of the economic burden of multiple sclerosis and cost-driving factors	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
Challenges in resource allocation of diagnostic tests in Spain	2
Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	2
Payer and Developer perspectives on alternative payment models	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
Advancing the economics of prevention: emerging methods and approaches	2
The utility and impact of digital endpoints for improving breast cancer outcomes	2
Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit	2
What to expect in 2024: important health economics and outcomes research (HEOR) trends	2
Estimated value of productivity lost due to childhood chickenpox in the United Kingdom: a survey of parents	2
The impact of non-pharmacological interventions on adherence to medication and persistence in dyslipidaemia and hypertension: a systematic review	2
Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers	2
Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	2
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	2
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital	2
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	2
Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab	2
Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions	2
Cost–utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain	2
How unprofessional behaviours between healthcare staff threaten patient care and safety	2
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs	2
Cost-effectiveness analysis of atezolizumab plus bevacizumab and chemotherapy for the treatment of metastatic, persistent, or recurrent cervical cancer (BEATcc)	2
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	2
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	2
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step	2
Cost-effectiveness of durvalumab with or without olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer	2
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	2
Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis	2
Identification of cognitively impaired patients at risk for development of Alzheimer’s disease dementia: an analysis of US Medicare claims data	2
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	2
A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials	2
Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program	2
Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis	1
Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review	1
Revival? Prospects for a return to comprehensive and coordinated health technology assessment in America	1
Story completion (SC) – an epistemological approach to the interpretation of patient-reported outcomes?	1
Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population	1
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events	1
A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer	1
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension	1
Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China	1
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore	1
The evolution and future of integrated evidence planning	1
Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review	1
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?	1
Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study	1
Cost-utility and budget impact analysis of CPAP therapy compared to no treatment in the management of moderate to severe obstructive sleep apnea in Colombia from a third-party payer perspective	1
Structural and socio-cultural barriers to HIV prevention tools among key populations: a scoping review	1
Cost-effectiveness studies of brexu-cel for relapsed/refractory B-cell acute lymphoblastic leukemia and mantle cell lymphoma: a systematic review	1
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China	1
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework	1
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies	1
Enhancing vaccine acceptance: a mixed methods approach to health promotion and willingness to pay among low-income Vietnamese communities	1
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder	1
Next-generation sequencing in oncology: challenges in economic evaluations	1
Medical oncologists’ dance with international guidelines and national reimbursement: insights from a survey in Türkiye	1
Use of the incremental cost-effectiveness ratio for decision-making policies—what is the problem? A perspective paper	1
A cost-effectiveness estimation of the Attempted Suicide Short Intervention Programme (ASSIP)	1
Cost of long-term care and balancing caregiver wellbeing: a narrative review	1
Evaluation of biological drug consumption in Italy during 2022: a comparative analysis between two healthcare facilities	1
HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework	1
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain	1
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer	1
A systematic review of cost-effectiveness studies of later-line treatments for refractory metastatic colorectal cancer	1
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	1
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy – a multi-center observational study within the CFHealthHub learning health system	1